Research · Sep 3, 2026
[VKTX] Viking Therapeutics Thesis 2026: A GLP-1-Amylin Obesity Biotech Rides Phase-3 and NASH
Viking Therapeutics, Inc. (NASDAQ: VKTX), headquartered in San Diego, California, is an emerging-GLP-1-and-amylin-obesity + emerging-NASH-FGF21 + emerging-diabetes-and-emerging-NASH-MASH-clinical-biotech providing distinctive multi-cycle Viking-Therapeutics VK2735-GLP-1-and-amylin + VK2809-NASH + emerging-pipeline pipeline to emerging-US-and-international-Endocrinologist + Hepatologist + emerging-Gastroenterologist + emerging-Pediatric-Neurologist + Medicare + Medicaid + emerging-commercial-payer customer base (post-clinical-approval future-state). Distinctive multi-cycle Brian-Lian-and-Viking-Therapeutics heritage: founded 2012 in San-Diego-CA by Brian Lian; April 2015 NASDAQ Viking-Therapeutics-IPO; multi-cycle 2015-2024 multi-cycle Viking-Therapeutics + multi-cycle-VK2735-Phase-1-Phase-2-clinical-trial + multi-cycle-VK2809-NASH-Phase-2-clinical-trial; March 2024 substantial VK2735-subcutaneous-Phase-2-positive-readout providing Phase-3-initiation; 2023 substantial VK2809-Phase-2b-positive-NASH-data. Multi-decade strategic-evolution: 2012-2015 Brian-Lian-and-Viking-Therapeutics-private platform; April 2015 NASDAQ-IPO; 2015-2024 multi-cycle Viking-Therapeutics + multi-cycle-VK2735-and-VK2809-clinical-trial; March 2024 substantial VK2735-subcutaneous-Phase-2-positive-readout; 2023 substantial VK2809-Phase-2b-positive-NASH-data; 2020-2025 substantial multi-cycle post-COVID + emerging-GLP-1-and-amylin-obesity-Eli-Lilly-Mounjaro-Zepbound-and-Novo-Nordisk-Ozempic-Wegovy-driven + emerging-NASH-FGF21-and-MASH + emerging-strategic-acquisition-target. Under founder-CEO Brian Lian (since 2014, ~11+ year founder-and-CEO + multi-cycle-Viking-Therapeutics expertise), FY2025 closes with selected various aggregate revenue ~$0M (pre-revenue clinical-stage), adj. EBITDA ~$-280-(-380)M, adj. EPS ~$-2.40-(-3.40), net cash ~$700-950M, and ~115-120M shares outstanding. The first deep-dive — VK2735 GLP-1-amylin obesity + VK2809 NASH + emerging-pipeline clinical franchise — covers entire VK2735-GLP-1-and-amylin + VK2809-NASH + emerging-VK0214-X-linked-Adrenoleukodystrophy + emerging-pipeline business + Viking-Therapeutics-and-emerging-Viking-Therapeutics positioning. Geographic + Pipeline composition: San-Diego-CA-Viking-Therapeutics-flagship + emerging-multi-jurisdiction-clinical-trial: VK2735-GLP-1-and-amylin-obesity (largest-pipeline-asset Phase-3-clinical-trial subcutaneous Q4-2024 + oral Q1-2025); VK2809-NASH-FGF21 (post-2023-Phase-2b-positive + emerging-Phase-3); Emerging VK0214 X-linked Adrenoleukodystrophy + Emerging-pipeline selective. Customer base (post-clinical-approval future-state): US-and-international-Endocrinologist + Hepatologist + Gastroenterologist + Pediatric-Neurologist + Medicare + Medicaid + commercial-payer + multi-cycle-Specialty-Pharmacy-channel. Competes with Eli Lilly (LLY largest-GLP-1-and-amylin-obesity-Mounjaro-and-Zepbound-and-emerging-Retatrutide most-direct-larger-Eli-Lilly-comp), Novo Nordisk (NVO largest-GLP-1-obesity-Ozempic-and-Wegovy-and-Saxenda most-direct-larger-Novo-Nordisk-comp), Roche (ROG-SW + Carmot-Therapeutics-acquired 2023 + CT-388), Amgen (AMGN + MariTide-AMG133-GLP-1-amylin), Structure Therapeutics (GPCR), Altimmune (ALT + pemvidutide-GLP-1-glucagon), Zealand Pharma (ZEAL-DK + petrelintide-amylin), Terns Pharmaceuticals (TERN), AstraZeneca (AZN + Eccogene-licensed-ECC5004), Pfizer (PFE + danuglipron-discontinued 2025), Sanofi (SAN-PA), Boehringer Ingelheim (private + survodutide-GLP-1-glucagon), Innovent Biologics (1801-HK + Mazdutide-Eli-Lilly-license-China); NASH-and-MASH Madrigal Pharmaceuticals (MDGL + Rezdiffra-2024-FDA-approval-largest-NASH-MASH most-direct-Madrigal-Rezdiffra-NASH-MASH-comp), Akero Therapeutics (AKRO + efruxifermin-FGF21), 89bio (ETNB + pegozafermin-FGF21), Inventiva (IVA-PA + lanifibranor-Phase-3); large-pharma Pfizer (PFE), Merck (MRK), Johnson & Johnson (JNJ), AbbVie (ABBV), Eli Lilly (LLY), Bristol-Myers Squibb (BMY), Amgen (AMGN), Gilead Sciences (GILD), Regeneron (REGN), Vertex Pharmaceuticals (VRTX), Sanofi (SAN-PA), GSK (GSK), AstraZeneca (AZN), Novartis (NVS), Roche (ROG-SW), Novo Nordisk (NVO). The second deep-dive — Brian-Lian + 2015-NASDAQ-IPO + multi-decade compounder thesis — covers Brian-Lian-founder-CEO + ~11+ year founder-and-CEO + multi-cycle-Viking-Therapeutics expertise, April-2015-NASDAQ-IPO + March-2024-VK2735-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data transformational-platform, emerging-US-and-international-GLP-1-and-amylin-obesity + emerging-NASH-and-MASH-FGF21 + emerging-substantial-strategic-acquisition-target structural-tailwinds. Multi-cycle-clinical-trial-and-emerging-investment-focused: no-regular-dividend + no-buyback. Multi-decade compounder thesis combines Brian-Lian-and-Viking-Therapeutics ~13+ year heritage, San-Diego-CA-Viking-Therapeutics-flagship-clinical-biotech, April-2015-NASDAQ-IPO + March-2024-VK2735-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data + multi-cycle-disciplined-clinical-trial-development, Brian Lian founder-CEO expertise, no-regular-dividend + no-buyback + non-IG balance-sheet (multi-cycle-cash-positive + emerging-substantial-strategic-acquisition-target potential), emerging-US-and-international-GLP-1-and-amylin-obesity + emerging-NASH-and-MASH-FGF21 + emerging-substantial-strategic-acquisition-target structural-tailwinds. Capital position is post-NASDAQ-IPO non-IG (B/B-), no-regular-dividend, no-buyback, multi-cycle-cash-positive: net cash ~$700-950M (zero-leverage, ~2-3 year clinical-trial-runway), B/B- equivalent, $700-950M cash + securities liquidity, FCF ~$-280-(-380)M/yr deployed into capex ~$8-25M/yr + no dividend + no buyback + multi-cycle-disciplined-clinical-trial-development + emerging-pipeline capex + occasional opportunistic-equity-issuance, ~115-120M shares. At ~$25-65 per share, equity value ~$2.9-7.8B, EV ~$2.2-7.1B (net cash), N/M EPS and N/M EV/EBITDA. Base case: VK2735-Phase-3-readout constructive + VK2735-oral-Phase-3 + VK2809-NASH-Phase-3 + emerging-pipeline + multi-cycle-clinical-trial-runway + ~10-50% return. Bull case: VK2735-Phase-3-readout positive-substantially (matching-or-exceeding-Eli-Lilly-Tirzepatide-and-Novo-Nordisk-Semaglutide-Wegovy efficacy + tolerability) + VK2735-oral-Phase-3 positive + VK2809-NASH-Phase-3 positive + emerging-substantial-strategic-acquisition-target (Eli-Lilly + Novo-Nordisk + Pfizer + Merck + AbbVie + Bristol-Myers-Squibb + AstraZeneca + Roche + Boehringer-Ingelheim + Sanofi + GSK interest substantial-emerging-strategic-acquisition-target for VK2735-GLP-1-and-amylin-obesity + VK2809-NASH-FGF21) + re-rate substantial + 100-300%+ return + substantial takeout-premium-upside. Bear case: VK2735-Phase-3-readout disappoints-or-fails + VK2809-NASH-Phase-3 disappoints + emerging-pipeline disappoints + adj. EBITDA $-450-(-550)M + adj. EPS $-3.80-(-4.80) + substantial-de-rate (50-80% decline + clinical-stage-binary-outcome-risk) + flat-to-substantially-negative-return.